GlassScriptPhysician profile
Cedric Ramon Willis
NPI 1801196589
$12,355.29
in general payments reported to CMS, 2019-2025
31 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,573 · 2022: $2,071 · 2023: $3,194 · 2024: $3,030 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,548 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,548.08 |
| Education | $163.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,865.34 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,765.02 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $936.87 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $567.27 | 2021-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $523.96 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $513.86 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $427.88 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $405.31 | 2024-2025 | Voquezna |
| Celgene Corporation | $377.86 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $331.17 | 2022-2025 | Ibsrela |
| Vivus LLC | $276.99 | 2021-2023 | Qsymia |
| Aimmune Therapeutics, INC. | $258.31 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $250.31 | 2024-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $239.35 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $217.86 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $210.12 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Intercept Pharmaceuticals, INC. | $201.63 | 2021-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $179.88 | 2022-2024 | Dupixent |
| Evoke Pharma, INC. | $170.45 | 2021-2025 | Gimoti |
| Enterra Medical, INC. | $154.72 | 2023 | |
| Pfizer INC. | $92.86 | 2021-2025 | |
| Braintree Laboratories, INC. | $67.83 | 2021-2024 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $65.79 | 2025 | Iqirvo |
| Medtronic, INC. | $57.77 | 2024-2025 | Interstim |
| Gilead Sciences, INC. | $55.28 | 2022-2025 | |
| Daiichi Sankyo INC. | $35.99 | 2021-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.32 | 2023 | Cyltezo |
| Novo Nordisk INC | $29.48 | 2025 | Wegovy |
| Amgen INC. | $17.94 | 2025 | Uplizna |
| Celltrion USA INC. | $15.39 | 2025 | Vegzelma |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cedric Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.